ストックスクリーナーアプリを入手
124.55
0.19%
-0.24
前日終値:
$124.79
開ける：
$123.78
24時間の取引高:
438.18K
Relative Volume:
0.55
時価総額：
$7.29B
収益：
$507.44M
当期純損益:
$-187.69M
株価収益率:
-38.08
EPS:
-3.271
ネットキャッシュフロー:
$-39.06M
1週間 パフォーマンス:
+4.23%
1か月 パフォーマンス:
+23.33%
6か月 パフォーマンス:
+56.73%
1年 パフォーマンス:
+37.99%
1日の値動き範囲:
$122.53
$127.00
1週間の範囲:
$118.57
$127.00
52週間の値動き範囲:
$73.16
$130.23
Glaukos Corp Stock (GKOS) Company Profile
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GKOS
Glaukos Corp
|
124.55 | 7.30B | 507.44M | -187.69M | -39.06M | -3.271 |
ABT
Abbott Laboratories
|
96.00 | 168.22B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
338.34 | 131.49B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
85.00 | 110.66B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
60.99 | 95.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
81.44 | 46.69B | 6.07B | 1.06B | 1.34B | 1.8063 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Buy |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 開始されました | Truist | Buy |
| 2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-14 | 再開されました | Stephens | Overweight |
| 2022-10-04 | 開始されました | Needham | Buy |
| 2022-07-12 | アップグレード | Stifel | Hold → Buy |
| 2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
| 2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
| 2020-12-09 | 開始されました | Oppenheimer | Perform |
| 2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 開始されました | Jefferies | Hold |
| 2020-03-05 | 開始されました | Citigroup | Sell |
| 2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-01-06 | アップグレード | Berenberg | Hold → Buy |
| 2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 開始されました | BTIG Research | Neutral |
| 2018-08-30 | 開始されました | Berenberg | Hold |
| 2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 繰り返されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-04-13 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-01-06 | アップグレード | Stifel | Hold → Buy |
| 2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corp (GKOS) 最新ニュース
Glaukos Corporation (GKOS) Stock Analysis: A Medical Device Innovator with 11.32% Potential Upside - DirectorsTalk Interviews
Glaukos’ Epioxa for keratoconus receives permanent J-code effective July 1, 2026 - Ophthalmology Times
Glaukos Releases Its 2025 Sustainability Report, Highlighting Key Milestones - VisionMonday.com
GLAUKOS Corp ($GKOS) CEO 2025 Pay Revealed - Quiver Quantitative
Glaukos receives new J-code for keratoconus treatment Epioxa By Investing.com - Investing.com Australia
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy - Yahoo Finance
Glaukos Announces the Release of its 2025 Sustainability Report - WFMZ.com
Glaukos Receives Permanent J-code for Epioxa™ - National Today
[ARS] GLAUKOS Corp SEC Filing - Stock Titan
Glaukos (NYSE: GKOS) 2026 proxy outlines board diversity, pay and ESG - Stock Titan
Glaukos Receives Permanent J-Code for Epioxa™ - National Today
Glaukos (GKOS) Secures J-Code for Epioxa Treatment - GuruFocus
Glaukos Receives Permanent J-code for Epioxa - National Today
Glaukos receives permanent J-code for Epioxa - TipRanks
Glaukos receives new J-code for keratoconus treatment Epioxa - Investing.com
[Form 4] GLAUKOS Corp Insider Trading Activity - Stock Titan
Glaukos Corporation (NYSE:GKOS) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-04-14 04:05:55 - baoquankhu1.vn
Street Watch: What chart patterns are forming on Glaukos Corporation2026 Institutional & Weekly Return Optimization Plans - baoquankhu1.vn
Glaukos (NASDAQ: GKOS) affiliate sale reported in Form 144 - Stock Titan
(GKOS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Glaukos sets April 29 earnings release, webcast after market close - Stock Titan
Glaukos to Release First Quarter 2026 Financial Results after Market Close on April 29 - Yahoo Finance
Citi Maintains Glaukos(GKOS.US) With Buy Rating, Raises Target Price to $135 - Moomoo
A Look At Glaukos (GKOS) Valuation As Epioxa Showcased At ASCRS Annual Meeting - simplywall.st
Glaukos Stock 5-Day Winning Spree: Stock Climbs 13% - Trefis
Does Glaukos (GKOS) Using Epioxa at ASCRS Hint at a Broader Corneal-Health Strategy Shift? - Yahoo Finance
Glaukos to Present Multiple Scientific Abstracts at ASCRS Annual Meeting - National Today
Glaukos to Present Multiple Scientific Abstracts at the 2026 American Society of Cataract and Refrac - PharmiWeb.com
Glaukos brings Epioxa symposium and 9 eye-care studies to ASCRS - Stock Titan
Capricorn Fund Managers Ltd Invests $6.78 Million in Glaukos Corporation $GKOS - MarketBeat
Q4 2024 Glaukos Corp Earnings Call Transcript - GuruFocus
Glaukos (NYSE: GKOS) CDO reports RSU tax withholding transactions - Stock Titan
Glaukos (NYSE: GKOS) CFO withholds 1,589 shares for RSU tax obligations - Stock Titan
Glaukos (GKOS) president uses 3,169 shares to cover tax withholding - Stock Titan
Glaukos (GKOS) CEO gifts 180,308 shares to family trust - Stock Titan
Glaukos Corp. Experiences Evaluation Revision Amidst Mixed Market Signals and Volatility - Markets Mojo
Cash per share of Glaukos Corp – DUS:6GJ - TradingView
Glaukos Corp (NYSE:GKOS) Shows High-Growth Momentum and Fits Key Trend Template Rules - ChartMill
Glaukos Corporation $GKOS Shares Acquired by Allspring Global Investments Holdings LLC - MarketBeat
GLAUKOS (GKOS) CDO has 5,798 shares withheld to cover RSU tax - Stock Titan
Glaukos Corporation (GKOS) Stock forecasts - Yahoo Finance UK
Glaukos Corporation (GKOS) Stock Forecasts - Yahoo Finance
GKOS PE Ratio & Valuation, Is GKOS Overvalued - intellectia.ai
SG Americas Securities LLC Purchases 49,492 Shares of Glaukos Corporation $GKOS - MarketBeat
Why Glaukos Stock Jumped Over 20% After-Hours Today - MSN
Alex Thurman: ‘Phenomenal Year’ for Glaukos - Orange County Business Journal
Price-Driven Insight from (GKOS) for Rule-Based Strategy - Stock Traders Daily
GKOS SEC FilingsGlaukos Corp 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Chart Watch: Does Glaukos Corporation stock have upside surprise potential2026 Major Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Glaukos breaks ground on $80M R&D, manufacturing facility in Alabama - MSN
Glaukos Corp (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.72%
大文字化:
|
ボリューム (24 時間):